Targeted temperature management following cardiac arrest in MD ANAESTHESIA

Reading File

Finding Sources

Searching PubMed

"targeted temperature management" AND "cardiac arrest"

Reading File

Finding Sources

I now have comprehensive content from multiple authoritative textbooks. Let me compile the full, detailed answer.

Targeted Temperature Management (TTM) Following Cardiac Arrest

(For MD Anaesthesia)

1. Introduction and Historical Background

Targeted temperature management (TTM) - previously called therapeutic hypothermia (TH) - refers to the intentional lowering and maintenance of core body temperature in comatose survivors of cardiac arrest to reduce neurological injury. The concept dates back over 5,000 years, with the first clinical trial in comatose cardiac arrest patients conducted in 1958.

Each year, approximately 350,000 persons in the United States experience an out-of-hospital cardiac arrest (OHCA); about 90% die. Devastating neurologic injury - particularly anoxic brain injury - is the leading cause of death and disability in those who achieve return of spontaneous circulation (ROSC). Over decades, pharmacologic interventions (steroids, barbiturates, nimodipine) all failed to show benefit. Hypothermia as a neuroprotective strategy was revisited in the late 1950s, with the modern era revived by two landmark 2002 trials.

(Miller's Anesthesia, 10e; Roberts and Hedges' Clinical Procedures in Emergency)

2. Mechanisms of Neuroprotection

Hypothermia protects the post-ischaemic brain through multiple complementary pathways:

Mechanism	Effect
Reduced cerebral metabolic rate	~6% reduction per 1°C decrease in brain temperature
Limitation of excitotoxicity	Reduced glutamate release
Free radical suppression	Decreased reactive oxygen species
Ion channel preservation	Maintained ion homeostasis; decreased intracellular Ca²⁺ influx
Apoptosis inhibition	Blocks intrinsic neuronal apoptotic cascades
Anti-inflammatory	Reduces cytokine production
Genetic/cell signalling	Alters cellular injury response pathways

Mild hypothermia (32-34°C) is easier to achieve and has fewer adverse effects than deeper temperatures, and has been consistently neuroprotective in experimental cerebral ischaemia models.

(Rosen's Emergency Medicine; Miller's Anesthesia, 10e)

3. Landmark Clinical Trials

3.1 The 2002 Trials (Foundation Evidence)

HACA Trial (Hypothermia After Cardiac Arrest Study Group, 2002)

Prospective randomised multicentre European trial
Cooling to 32-34°C within 6 hours for up to 24 hours following OHCA (shockable rhythm: VF/VT)
Significantly improved neurologically intact survival at 6 months
Number Needed to Treat (NNT) = 6 - a profound clinical benefit
55% of hypothermia-treated patients achieved good Cerebral Performance Score (1 or 2), vs 39% controls (absolute difference 16%, NNT ~8)
6-month mortality: 41% (hypothermia) vs 55% (controls)

Bernard et al. (2002)

Confirmed similar findings; cooling to 33°C within 2 hours and maintained for 12-24 hours

Based on these two trials, ILCOR incorporated TH into post-cardiac arrest recommendations in 2003.

3.2 Nielsen TTM Trial (2013)

Large prospective randomised multicentre trial
Compared active cooling to 33°C vs 36°C for 24 hours following OHCA, with temperature control <37.5°C for 72 hours post-ROSC
Both groups showed similar mortality and neurological benefit at 180 days
Important caveat: Nielsen patients were less severely injured (higher bystander CPR rates, higher STEMI rates amenable to PCI, survived to ICU rather than enrolled in ED)
Conclusion: Active cooling was required even to achieve 36°C - this does not mean cooling is unnecessary

3.3 Non-Shockable Rhythm Trial

Compared normothermia to mild hypothermia at 33°C for OHCA with initial non-shockable rhythm
Demonstrated significantly better neurological outcomes in the hypothermia group - near doubling of favourable neurologic function at 90 days (10.2% vs 5.7%)

3.4 Duration Trial

A recent study found no benefit of 48-hour TTM at 33°C compared to 24 hours, while longer intervals were associated with more adverse events

3.5 Paediatric - THAPCA-OH Trial

Compared TTM to 33°C vs therapeutic normothermia (36.8°C) in paediatric OHCA
No significant difference in good neurological outcome at 12 months
Caveats: leading cause of paediatric arrest was respiratory (72%), shockable rhythm only 8% - very different population from adult trials

(Roberts and Hedges'; Rosen's Emergency Medicine)

4. Current Recommendations (AHA 2015 Guidelines)

Parameter	Recommendation
Indication	All comatose adult patients (lacking meaningful response to verbal commands) with ROSC after cardiac arrest
Target temperature	32°C to 36°C - selected and achieved, then maintained constantly for at least 24 hours
Beyond 24 hours	Actively preventing fever (normothermia) in comatose patients after TTM is reasonable
Neuroprognostication	Earliest: 72 hours after cardiac arrest; may be longer if sedation/paralysis effects persist

ILCOR 2015: Allows a wider target temperature range (32-36°C) based on injury severity and individual patient characteristics.

5. Inclusion and Exclusion Criteria

Inclusion Criteria (Tintinalli Table 26-1)

Post-resuscitation ROSC
GCS motor score < 6
No other reason for coma
No DNR or DNI status
Adult (age > 17 years)

Exclusion Criteria

Awake/alert after cardiac arrest
Arrest of traumatic etiology
Arrest associated with significant bleeding
Pre-existing coma or vegetative state
Pregnancy (relative - several case reports show good outcomes)
DNR/DNI status

NOT an Exclusion Criterion

Patient on warfarin or heparin (therapeutic anticoagulation is NOT a contraindication)
Initial arrest rhythm was non-shockable
Long QT syndrome

(Tintinalli's Emergency Medicine)

6. Cooling Methods and Devices

6.1 Induction Phase

Method	Details
Cold IV saline	1-2 L of 4°C (39.2°F) isotonic saline - rapid, simple, facilitates induction
Ice packs	Applied to neck, axillae, inguinal areas
Fan cooling	Of dampened exposed skin
Cooling blankets	Disable ventilator warming circuits
Intranasal cooling	Transnasal evaporative cooling devices

6.2 Maintenance Phase (Temperature-Controlled Devices)

Device Type	Features
Surface cooling pads	Chest + thigh pads with continuous temperature feedback; temperature SD ~0.5°C
Endovascular cooling catheter	Central venous catheter; tightest temperature control (SD usually <0.3°C); more invasive
Automated esophageal cooling	Orogastric silicone tube; tight control

Temperature monitoring: Indwelling temperature-sensitive bladder catheter or esophageal temperature probe (both are preferred for redundancy - esophageal feeds cooling device, bladder feeds monitoring system).

Note: No single cooling strategy or device has been shown to produce superior clinical outcomes. Prehospital cooling with cold IV saline has NOT shown benefit in three prospective randomised trials and is not recommended.

(Rosen's Emergency Medicine; Roberts and Hedges')

7. Step-by-Step Protocol (Abbreviated - BOX 4.1)

Evaluate adult cardiac arrest survivors for appropriateness of TTM
Begin cooling - rapid infusion of 2 L of cold (4°C) IV saline immediately after arrival/ROSC
Expose patient; avoid external warming (no blankets, no heated ventilator circuit)
Place temperature-sensing urinary catheter + esophageal temperature probe
Initiate definitive cooling via endovascular or surface device at maximal rate to target 33°C
Prevent shivering - sedation + non-depolarising neuromuscular blockade (bolus in ED, infusion in ICU)
Avoid hypotension and hypoxia
Do not delay primary PCI for STEMI - initiate TTM simultaneously
Admit to ICU
Continuous EEG monitoring for occult status epilepticus; treat seizures if present
Manage ABGs consistently (pH-stat or alpha-stat - choose one)
At 24 hours: begin rewarming to 36.5°C at 0.15°C/hour
Discontinue paralytics at onset of rewarming; control shivering with sedation + surface counterwarming
Lighten sedation progressively as rewarming progresses
Discontinue endovascular device after 48 hours (can maintain normothermia until removal)
Neurological evaluation before 72 hours; neurology consultation

(Rosen's Emergency Medicine, Box 4.1)

8. Rewarming

Rate: 0.15°C/hour (active, controlled rewarming)
Target: 36.5°C
Duration of rewarming phase: 12-16 hours
Post-rewarming: Active fever suppression at normothermia (37.0°C) for 72 additional hours
Rebound hyperthermia is common with passive rewarming and must be avoided - it worsens neurological outcome
Passive rewarming or combined passive + slow active rewarming are used in various protocols

9. Complications and Management

Complication	Notes and Management
Shivering	Most common; inhibits cooling; treat with sedation (propofol, opioids) + neuromuscular blockade (vecuronium/rocuronium)
Seizures	5-20% of post-cardiac arrest patients; continuous EEG recommended; treat with IV lorazepam 0.1 mg/kg (max 4 mg), diazepam 0.15-0.2 mg/kg (max 10 mg), or IM midazolam 0.2 mg/kg (max 10 mg)
Coagulopathy	Lowered temperatures increase bleeding risk; monitor closely
Infections	Hypothermia impairs immune function; watch for pneumonia, sepsis
Electrolyte disturbances	Cold diuresis causes hypokalemia, hypomagnesemia, hypophosphatemia - monitor and replace
Bradycardia	Often well tolerated; usually does not require treatment
Insulin resistance/hyperglycaemia	Hypothermia causes insulin resistance; monitor BGL; tight glucose control
Drug metabolism	Hypothermia slows drug clearance - sedative and analgesic doses may need adjustment

Bleeding risk: In the four major randomised TTM trials, bleeding complications were NOT statistically different between hypothermia and normothermia groups. Thrombolytic therapy does NOT preclude use of hypothermia.

10. TTM and Concurrent PCI

STEMI: Immediate PCI is indicated; TTM should not delay door-to-balloon time
If cath lab is immediately available: initiate TTM in the lab, not the ED
If ED time permits before lab is ready: initiate cooling in ED
TTM can be continued safely throughout the catheterisation procedure
Neurological status should NOT be considered a contraindication to immediate angiography/PCI

In one study, 50% of ROSC patients had acute coronary occlusion on catheterisation; >10% had no ST elevation - suggesting low threshold for angiography.

11. Neuroprognostication After TTM

Because patients receive high-dose analgesia and sedation for 24-48 hours during TTM, accurate prognostication requires additional time for drug clearance:

Minimum 72 hours after cardiac arrest before prognostication
Multimodal approach is essential - no single test is reliable alone

Poor Neurological Outcome Indicators (High Specificity)

Finding	Timing	Significance
Bilaterally absent pupillary light reflex	72 hours	Highly predictive, low false-positive rate
Bilateral absent cortical N20 SSEP responses	After rewarming / 24-72 h	Highly predictive
Absent corneal reflexes	72 hours	Supportive
Absent EEG reactivity or burst-suppression	After rewarming	Supportive
Myoclonic status epilepticus	Early	Supportive
Diffuse anoxic injury on CT/MRI	Any time	Supportive
Elevated NSE (neuron-specific enolase)	Not standardised - use with caution

Early examination findings (absent pupillary and corneal reflexes) are poorly predictive in the first 24-48 hours and should not trigger premature withdrawal of care.

12. Special Populations

Paediatric

Indications not as well established as adults
Hypothermia improves outcomes in neonatal hypoxic-ischaemic encephalopathy (established standard of care)
AHA 2015: Comatose paediatric patients after OHCA - either TTM to 32-34°C or normothermia (36-37.5°C) is acceptable
At minimum: careful avoidance of post-arrest fever is important

Pregnant Patients

Listed as exclusion in many protocols, but case reports show good outcomes
Several systematic reviews have evaluated TTM in pregnancy - case-by-case assessment is recommended

Non-Shockable Rhythms (PEA/Asystole)

Original trials enrolled only VF/VT patients
Clinical evidence and recent trials suggest TTM also improves outcomes for PEA/asystole
Rosen's and ILCOR recommend TTM for all comatose post-arrest patients regardless of presenting rhythm

In-Hospital Cardiac Arrest (IHCA)

TTM is recommended for comatose survivors of IHCA as well as OHCA

13. Intra-Arrest Therapeutic Hypothermia (IATH) - Emerging Concept

An evolving concept where cooling is initiated during CPR before ROSC. Animal models show:

Cooling to 32°C during CPR is highly protective of heart and brain
Protection is lost if cooling is delayed by even 20 minutes
A critical therapeutic window exists during CPR

This remains clinically challenging to implement and is not yet standard practice, but ILCOR has highlighted its potential to exceed benefit of post-ROSC TTM alone.

14. Key Points Summary

Parameter	Current Best Practice
Indication	All comatose adults with ROSC post-cardiac arrest
Target temperature	32-36°C (commonly 33°C)
Initiation	As soon as possible after ROSC; in the ED
Duration	Minimum 24 hours at target temperature
Rewarming	Controlled, 0.15°C/h to 36.5°C over 12-16 hours
Post-rewarming	Active fever prevention at ≤37°C for 72 h
Prehospital cooling	NOT recommended
Prognostication	Not before 72 hours; multimodal
Thrombolytics/anticoagulants	Not a contraindication
PCI for STEMI	Do not delay; TTM can run concurrently

Recent Evidence Update (2023-2026)

A 2023 systematic review and meta-analysis by Chiu et al. (PMID 37421815) confirmed benefit of therapeutic hypothermia after cardiac arrest from RCT-level evidence. A 2025 review on cooling methods and devices (PMID 40693584) summarised current and emerging cooling technologies. A 2026 systematic review and meta-analysis (PMID 40956682) examined TTM strategies specifically in paediatric OHCA patients.

No recent systematic reviews fundamentally contradict the TTM evidence base, though the optimal target temperature (33°C vs 36°C) continues to be refined.

Sources:

Miller's Anesthesia, 10e (9780323935920), Block 34
Rosen's Emergency Medicine: Concepts and Clinical Practice (9780323757898), Blocks 1, 29
Tintinalli's Emergency Medicine: A Comprehensive Study (9781260019933), Blocks 2, 3
Roberts and Hedges' Clinical Procedures in Emergency Medicine (9780323354783), Block 14
AHA 2015 TTM Guidelines (incorporated in all the above)

This is a shared conversation. Sign in to Orris to start your own chat.